Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MVD | P53602 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | CTSL | P07711 | 1/20 | 0.33 |
| ▸ | CTSB | P07858 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL52467 | 0.86 | HDAC6 (0.40) | HDAC6HDAC1HDAC2CTSLCTSB | |
| SCHEMBL25133621 | 0.84 | MVD (0.39) | MVDHDAC6HDAC1HDAC2CTSL | |
| SCHEMBL21069315 | 0.84 | MVD (0.39) | MVDHDAC6HDAC1HDAC2CTSL | |
| SCHEMBL25134161 | 0.84 | MVD (0.39) | MVDHDAC6HDAC1HDAC2CTSL | |
| SCHEMBL397071 | 0.84 | MVD (0.39) | MVDHDAC6HDAC1HDAC2CTSL | |
| SCHEMBL22572467 | 0.84 | KDM4E (0.35) | HDAC6HDAC1HDAC2CTSLCTSB | |
| SCHEMBL336495 | 0.80 | HDAC6 (0.37) | MVDHDAC6HDAC1HDAC2CTSL | |
| Ammonia Solution, Strong SCHEMBL29062672 | 0.78 | HDAC6 (0.36) | MVDHDAC6HDAC1HDAC2CTSL | |
| SCHEMBL20188230 | 0.74 | ALDH1A1 (0.43) | — | |
| SCHEMBL22690216 | 0.73 | MVD (0.36) | MVDHDAC6HDAC1HDAC2CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4029868-B1 | MCL-1 INHIBITORS | GILEAD SCIENCES INC (US) | 2026-05-20 | — | — | EP | disclosed |
| CN-117304130-A | MCL-1 inhibitors | 吉利德科学公司 | 2023-12-29 | — | — | CN | disclosed |
| US-20230312490-A1 | MCL-1 INHIBITORS | GILEAD SCIENCES, INC. | 2023-10-05 | — | — | US | disclosed |
| US-20230312490-A1 | MCL-1 INHIBITORS | GILEAD SCIENCES, INC. | 2023-10-05 | — | — | US | disclosed |
| US-20230312490-A1 | MCL-1 INHIBITORS | GILEAD SCIENCES, INC. | 2023-10-05 | — | — | US | disclosed |
| CN-112118845-B | MCL-1 inhibitors | 吉利德科学公司 | 2023-06-13 | — | — | CN | disclosed |
| US-11643400-B2 | MCL-1 inhibitors | GILEAD SCIENCES, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| US-11643400-B2 | MCL-1 inhibitors | GILEAD SCIENCES, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| US-11643400-B2 | MCL-1 inhibitors | GILEAD SCIENCES, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| US-20220340535-A1 | MCL-1 INHIBITORS | GILEAD SCIENCES, INC. | 2022-10-27 | — | — | US | disclosed |
| EP-4029868-A1 | MCL-1 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2022-07-20 | — | — | EP | disclosed |
| EP-3793565-B1 | MCL-1 INHIBITORS | GILEAD SCIENCES INC (US) | 2022-01-05 | — | — | EP | disclosed |
| US-10988451-B2 | MCL-1 inhibitors | GILEAD SCIENCES, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| EP-3793565-A1 | MCL-1 INHIBITORS | Gilead Sciences, Inc. (US) | 2021-03-24 | — | — | EP | disclosed |
| CN-112118845-A | MCL-1 inhibitors | 吉利德科学公司 | 2020-12-22 | — | — | CN | disclosed |
| US-20200331870-A1 | MCL-1 INHIBITORS | GILEAD SCIENCES, INC. | 2020-10-22 | — | — | US | disclosed |
| US-10703733-B2 | MCL-1 inhibitors | GILEAD SCIENCES, INC. (US) | 2020-07-07 | — | — | US | disclosed |
| US-10703733-B2 | MCL-1 inhibitors | GILEAD SCIENCES, INC. (US) | 2020-07-07 | — | — | US | disclosed |
| US-20190352271-A1 | MCL-1 INHIBITORS | GILEAD SCIENCES, INC. | 2019-11-21 | — | — | US | disclosed |
| US-20190352271-A1 | MCL-1 INHIBITORS | GILEAD SCIENCES, INC. | 2019-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190352271-A1 | MCL-1 INHIBITORS | MCL1, BCL2L1, BCL2 | MVD 3068/4885HDAC6 178/4885HDAC1 204/4885 |
| US-20200331870-A1 | MCL-1 INHIBITORS | MCL1, BCL2L1, BCL2 | MVD 3068/4885HDAC6 178/4885HDAC1 204/4885 |
| US-20230312490-A1 | MCL-1 INHIBITORS | MCL1, BCL2L1, BCL2 | MVD 3068/4885HDAC6 178/4885HDAC1 204/4885 |
| US-10703733-B2 | MCL-1 inhibitors | MCL1, BCL2L1, BCL2 | MVD 3068/4885HDAC6 178/4885HDAC1 204/4885 |
| US-11643400-B2 | MCL-1 inhibitors | MCL1, BCL2L1, BCL2 | MVD 3068/4885HDAC6 178/4885HDAC1 204/4885 |
| US-10988451-B2 | MCL-1 inhibitors | MCL1, BCL2L1, BCL2 | MVD 3068/4885HDAC6 178/4885HDAC1 204/4885 |
| US-20220340535-A1 | MCL-1 INHIBITORS | MCL1, BCL2L1, BCL2 | MVD 3068/4885HDAC6 178/4885HDAC1 204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.